deposition in the microvasculature and an increased bleeding tendency. The ongoing thrombotic process impedes adequate oxygen delivery to many organs and may thereby be a significant factor in the development of multiple organ dysfunction. [2] [3] [4] The bleeding tendency is caused by ongoing activation of the hemostatic system, causing consumption and subsequent exhaustion of clotting factors and platelets, accompanied by reduced synthesis and enhanced degradation of these factors and their inhibitors. As a result, a hemorrhagic tendency may occur, sometimes resulting in spontaneous profuse bleeding from various sites.
Many dysfunctional organs in patients affected by DIC display intravascular fibrin deposition at microscopic examination. 
| CLINIC AL COND ITI ON S KNOWN TO B E A SSO CIATED WITH D I C
It should be stressed that DIC is not an independent clinical condition but is always a complication of another disease that results in the activation of coagulation. 8 The clinical settings most commonly underlying DIC are listed in Table 1 For other underlying conditions (Table 1) , DIC is a relatively uncommon consequence. In the majority of settings, the intensity of the associated systemic inflammatory reaction in combination with specific conditions, such as concomitant infections, will determine whether DIC will occur. 14 Thrombin production in DIC originates through activation of the tissue factor/factor VII(a) pathway that will subsequently cause factor Xa and IXa generation. 15 Tissue factor may be exposed by activated mononuclear cells but also by endothelial cells or malignant cells. In DIC, all natural anticoagulant pathways are functionally defective. 5 A significant imbalance of tissue factor pathway inhibitor (TFPI) function compared to the increased tissue factor-dependent coagulation activation has been reported. 16 In addition, a serious deficiency of the protein C system may further impede adequate inhibition of thrombin generation. The impairment in the protein C pathway is caused by a downregulation of thrombomodulin expression on endothelial cells in combination with decreased synthesis and enhanced degradation of protein C. 17 Also, plasma levels of antithrombin, the principal inhibitor of thrombin, are significantly decreased in DIC, due to concurrent consumption, impaired synthesis, and degradation by elastase from activated neutrophils. 5 On top of that, endogenous fibrinolysis is largely inactive due to a sustained rise in plasminogen activator inhibitor-1 (PAI-1), the most important regulator of plasminogen activation and plasmin generation. 
| PATHOG ENE S IS OF D I C

| DIFFERENTIAL L ABOR ATORY D IAG NOS IS OF D I C
The typical laboratory signature of DIC is a coagulopathy characterized by a low (or decreasing) platelet count, prolonged global coagulation assays, and increased fibrin degradation products (such as D-dimer). These laboratory abnormalities may be compatible with DIC; however, some differential diagnostic considerations needs to be taken into account. 18 It may be challenging to differentiate DIC from the coagulation defect due to excessive blood loss and the dilutional coagulopathy caused by massive infusion of large volumes of plasma expanders that may take place in the first hours after major trauma. Prospective studies have demonstrated that the sensitivity of the DIC algorithm is 93%, with a specificity of 98%. 6 Similar scoring algorithms have been developed and extensively evaluated in various countries.
Point-of-care tests are increasingly employed in patients with a coagulopathy related to critical illness, including DIC. tify relevant coagulation changes. 23 There was also a relationship between abnormalities in thromboelastography (in particular parameters reflecting speed of clot formation and clot strength) and reduced survival. The use of thromboelastography for the diagnosis of DIC has not been systematically studied although some authors believe that the test may be useful for appraising coagulopathies in critically ill patients. 24 Another test to assess hypercoagulability in critically ill patients is the activated partial thromboplastin (aPTT) biphasic waveform analysis that can be detected on some optical coagulation analyzers.
The biphasic waveform is related to the occurrence of complexes of very-low-density lipoprotein and C-reactive protein, and its presence was shown to have more than 90% accuracy for development of DIC and an adverse outcome. 25 
| D I C OR LIVER FAILURE?
In patients with severe hepatic failure, a myriad of changes in coagulation can be observed. More than 75% of patients with cirrhosis have thrombocytopenia (platelets <150×10 in severe liver disease, the (low) platelet count is usually stable and fibrin degradation markers (such as D-dimer) are only mildly increased. 28, 29 As the alpha subunit of factor XIII is produced in magakaryocytes and white blood cells, levels of factor XIII may remain relatively stable in patients with impaired liver function despite decreased production of the beta subunit in the liver, whereas in DIC, factor XIII levels are usually low. In addition,
clinical signs, such as the presence of splenomegaly and ascites, may indicate that liver disease rather than DIC is the cause of the coagulopathy.
| THROMBOTIC MICROANG IOPATHY AND D I C
The presence of thrombocytopenia and schistocytes in the blood film may point in the direction of a thrombotic microangiopathy, such as thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome. However, these syndromes are typically accompanied by normal clotting times and normal or only slightly elevated D-dimer.
Schistocytes may also be seen in patients with DIC as a result of enhanced platelet-vessel wall interaction and formation of microvascular thrombotic obstruction, causing mechanical damage to erythrocytes.
Similar to other types of thrombotic microangiopathy, that associated with DIC is caused by an enhanced platelet-vessel wall interaction.
A crucial factor in the pathogenesis of this enhanced platelet-vessel wall interaction is thought to be the release of (ultralarge) von
Willebrand factor multimers as a result of inflammation-induced endothelial cell perturbations. von Willebrand factor is an acute phase protein that is markedly upregulated and released during systemic inflammation. Several studies have focused on ADAMTS13 levels in patients with sepsis. Up to one-third of patients with sepsis have ADAMTS13 levels that are <50% of normal. 30, 32 One study reported that about 15% of patients had severely reduced (<10%) ADAMTS13 levels; however, it should be noted that this study was carried out in Japanese
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LEVI patients who have a relatively high frequency of the ADAMTS13 p.P475S polymorphism (allele frequency approximately 10%), which is urea-sensitive. As ADAMTS13 levels in this study were measured with a urea-based assay, these much reduced levels may have been spuriously low. 32 Studies in septic children also report decreased ADAMTS13 levels in the majority of cases, with the deficiency strongly correlating to a more severe coagulopathy. 35, 36 Low levels of ADAMTS13 in sepsis are associated with reduced concentrations of cleaved von Willebrand factor. 37 Low levels of ADAMTS13 are also seen more frequently in patients with overt DIC and are strongly correlated with more severe renal insufficiency. 32, 38 The decrease in ADAMTS13 levels appears to be clearly associated with severity and increasing organ failure scores. Interestingly, plasma levels of ADAMTS13 were significantly lower (mean levels 31%) in patients with sepsis compared to patients with other systemic inflammatory conditions with a non-infective etiology (mean levels 56%).
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A strong association is reported between the magnitude of decrease in ADAMTS13 levels in patients with sepsis and an adverse outcome. Significantly lower ADAMTS13 levels are seen at the time of intensive care admission in eventual non-survivors. 40 Patients with ADAMTS13 plasma concentrations ≤50% had an approximate 10% higher risk of death compared with patients who present with no or only mild reduction in ADAMTS13 levels. 35 One recent study demonstrated an approximate 50% lower survival rate in patients (mortality 59%) with septic shock and ADAMTS13 levels <30%, compared with patients having higher levels of ADAMTS13 (mortality 28%). The predictive value of ADAMTS13 deficiency for mortality was as powerful as APACHE II or similar risk scores.
| CON CLUS ION
DIC is a disease state manifested by concurrent systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, and ongoing consumption of platelets and coagulation factors, which may cause widespread bleeding complications. DIC is always secondary to an underlying condition, such as sepsis, cancer, major trauma, or obstetric
catastrophes. An accurate diagnosis of DIC can be made through simple scoring systems based on routinely available coagulation laboratory tests. A differential diagnosis may include dilutional coagulopathies, the coagulation derangement associated with liver failure, and thrombotic microangiopathies (that may also occur in combination with DIC).
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